Timothy A Chan
Case Comprehensive Cancer Center, Cleveland Clinic Center for Immunotherapy and Immuno-Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Timothy A Chan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:29 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07695311 · EWSR1 Immunotherapy in Ewing Sarcoma and DSRCTRabi Hanna · not yet recruiting · Ewing Sarcoma, Desmoplastic Small Round Cell Tumor · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 15 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination TherapiesU54CA274513 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · fiscal years 2022 to 2026 · $1,518,487 awarded in 2026Same name and institution; not confirmed by an ID
- Homologous recombination repair pathway mutations and genetic mechanisms shaping anti-tumor immunity and immunotherapy efficacyR01CA294640 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · fiscal years 2025 to 2026 · $698,349 awarded in 2026Same name and institution; not confirmed by an ID
- Immune OncologyP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · fiscal years 2025 · $85,361 awarded in 2025Same name and institution; not confirmed by an ID
- Pre-exposure Immunologic Health and Linkages to SARS-COV2 Serologic Responses, Endothelial Cell Resilience, and Cardiovascular Complications: Defining the mechanistic basis of high risk endotypes.U01CA260513 · NCI · CASE WESTERN RESERVE UNIVERSITY · fiscal years 2020 to 2024 · $433,161 awarded in 2024Same name and institution; not confirmed by an ID
- Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and ResistanceR35CA232097 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · fiscal years 2018 to 2024 · $961,680 awarded in 2024Same name and institution; not confirmed by an ID
- Elucidating genetics of response to immune checkpoint blockade in lung cancerR01CA205426 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · fiscal years 2017 to 2021 · $418,751 awarded in 2021Same name and institution; not confirmed by an ID
- Elucidating and targeting the molecular foundations of IDH Mutant gliomaR01CA177828 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · fiscal years 2015 to 2019 · $74,890 awarded in 2019Same name and institution; not confirmed by an ID
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in ewing sarcoma.